Prevalence of lipohypertrophy and associated risk factors in insulin-treated patients with type 2 diabetes mellitus

International Journal of Endocrinology and Metabolism

Volumn 13, Issue 2, 2015, Pages

  Al Ajlouni, Mo'men ^a   Abujbara, Mousa ^b   Batieha, Anwar ^c   Ajlouni, Kamel ^b  

^a Prince Sultan Cancer Center   (Saudi Arabia)

^b National Center for Diabetes Endocrinology and Genetics Jordan   (Jordan)

^c JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

Diabetes mellitus; Insulin; Lipodystrophy

Indexed keywords

INSULIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HUMAN; INJECTION SITE; JORDAN; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; NEEDLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PHYSICAL EXAMINATION; PREVALENCE; RISK FACTOR; TREATMENT DURATION; VERY ELDERLY;

EID: 84929012623     PISSN: 1726913X     EISSN: 17269148     Source Type: Journal    
DOI: 10.5812/ijem.20776     Document Type: Article

References (14)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.
2. Fujikura J, Fujimoto M, Yasue S, Noguchi M, Masuzaki H, Hosoda K, et al. Insulin-induced lipohypertrophy: report of a case with histopathology. Endocr J. 2005;52(5):623-8.
3. Seyoum B, Abdulkadir J. Systematic inspection of insulin injection sites for local complications related to incorrect injection technique. Trop Doct. 1996;26(4):159-61.
4. Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol. 2003;4(10):661-7.
5. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes. 1996;104(2):106-10.
6. Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013;39(5):445-53.
7. Carr DB, Utzschneider KM, Hull r. l., Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes Metab. 1996;53:2087-94.
8. American Diabetes A. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34 Suppl 1:S11-61.
9. Kasha Z, Haiheydan Z, Akha O, Akbarzadeh S. Prevalence of lipodystrophy associated with recombinant insulin. Mazandaran Uni Med Sci J. 2008;18:9.
10. Chowdhury TA, Escudier V. Poor glycaemic control caused by insulin induced lipohypertrophy. BMJ. 2003;327(7411):383-4.
11. Hambridge K. The management of lipohypertrophy in diabetes care. Br J Nurs. 2007;16(9):520-4.
12. Sea-de Ibarra L, Gallego F. Factors related to Lipohypertrophy in insulin-treated diabetic patients: role of educational intervention. Practical Diab Int. 1998;15(1):9-11.
13. Malwa G, Balami D, Deshmukh S, Groft M, Bodmer C, Patel M. Insulin-induced Lipohypertrophy, past present and future: are we lose the bottle. Endocrine. 2010;22:268.
14. Vardar B, Kizilci S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007;77(2):231-6.